BackAlnylam Pharmaceuticals Overview

Alnylam Pharmaceuticals Selling, General & Admin

Selling, General & Admin expenses for ALNY.

Quarterly SG&A Expenses

$322.55M
↑ 34.42% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$1.29B
↑ 28.73% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin